admin – Page 2779 – Get News Story

5Strands’ Pet Test Demonstrates Wellness Benefits in 3rd Party Study

Pet parents across the U.S. are increasingly seeking answers to unexplained skin irritation, digestive distress, and behavioral changes in their pets. With growing awareness of food intolerances and environmental sensitivities, the demand for personalized, non-invasive wellness solutions is rising fast. 5Strands is leading the way with their pet intolerance, sensitivity, and imbalances tests, designed to help pet owners make smarter choices to restore their pet’s health and vitality.

But, for solutions to truly stand out in a crowded market, science-backed validation is essential. That’s where consumer perception studies come into play; offering real-world insight into how products perform in everyday settings. For 5Strands, this kind of research not only supports their product claims but builds trust within the pet health community.

In a recent consumer perception study conducted by Citruslabs, the Pet Intolerances & Imbalances Test demonstrated notable improvements in pets’ vitality, digestion, and behavior after owners adjusted their pets’ diets and environments based on the test results. By Day 45 of using the product:

– 81.3% of participants said they would use the test again for other pets.

– 71.9% agreed that the test allowed them to make changes that improved their pet’s life.

– 68.8% would recommend the test to friends and family.

– 62.5% of pets experienced no upset stomachs in the last 15 days (up from 44.4% at Baseline).

– 81.25% of pets experienced no diarrhea (up from 63.9%), and 65.63% experienced no vomiting (up from 55.6%).

“These results are a strong affirmation of what we hear from customers every day: our test helps pets feel better,” said Austin Collins, CEO at 5Strands. “We’re proud to offer a tool that empowers pet owners to take their pet’s health into their own hands with clarity and confidence”

Unlike conventional pet wellness products that treat symptoms without addressing root causes, 5Strands’ test identifies potential intolerances and imbalances, ranging from food ingredients to environmental factors, so that pet owners can create tailored plans to improve their pets’ overall health and comfort. The test also scored highly on user-friendliness:

– 100% of participants said the instructions were easy to follow.

– 69.4% agreed the test report clear and easy to understand.

– 61.1% were able to interpret the results without veterinary assistance.

In addition to improvements in digestive and skin health, owners observed increased eagerness to eat and reduced signs of discomfort such as excessive scratching, chewing, or biting of irritated areas.

As more pet parents demand proactive, personalized health insights, 5Strands continues to innovate with science at their core. The Citruslabs study confirms that the Pet Intolerances & Imbalances Test is more than just a diagnostic tool, it’s a trusted solution for the future of pet wellness.

To learn more about 5Strands’ pet intolerance, sensitivity, and imbalance tests, visit www.5strands.com.

About 5Strands

Founded to revolutionize pet and human health diagnostics, 5Strands offers non-invasive hair testing that uncovers potential intolerances to food and environmental triggers. With easy-to-understand results and actionable insights, 5Strands empowers families to take control of their wellness journeys. Learn more at www.5strands.com.

Media Contact
Company Name: 5Strands
Contact Person: Lisa Blaurock
Email: Send Email
Phone: +1 (833) 600-8378
Country: United States
Website: https://www.5strands.com/

Freight My Car Reports Seasonal Surge in UAE to Europe Vehicle Air Freight

Freight My Car confirms a notable increase in vehicle air freight bookings from Dubai to Europe during the summer season, driven by high-net-worth travelers opting for personal vehicle transport during extended overseas stays.

Freight My Car has reported a seasonal rise in demand for vehicle air freight services from the United Arab Emirates to various European destinations. The trend has been observed between May and August every year and reflects a growing preference among residents to travel with their personal vehicles during long-stay summer visits abroad.

The Dubai-based logistics company confirmed a significant increase in summer air freight bookings. High-value vehicles, including luxury SUVs and performance cars, are being shipped via scheduled cargo flights departing from Dubai International Airport and Al Maktoum International Airport.

Freight My Car offers complete vehicle transport support, including pickup, assistance with Carnet de Passage issuance, RTA documentation, pre-departure inspection, insurance coverage in Europe, customs clearance on arrival and delivery until doorstep. Transit times to Europe typically range from 48 hours to 5 days depending on the destination, carrier, schedules and space availability. The company maintains logistics partnerships in Europe to support smooth vehicle processing and final delivery.

“Clients value the familiarity and reliability of using their own vehicles abroad, especially when staying for extended periods,” said Sachin Manwani, CEO of Freight My Car. “The growth reflects a broader shift in travel preferences among UAE residents who prioritize control and comfort during their seasonal relocations.”

The majority of vehicle shipments are destined for France, Switzerland, Germany, and Spain, where many clients either own property or plan extended stays. These preferences are contributing to the demand for secure, high-speed international auto transport services.

Once delivered, many travelers use their vehicles to explore Europe’s scenic routes—from the coastal highways of the Cote d’Azur to the mountain passes of the Swiss Alps—taking advantage of the cooler summer weather and the comfort of familiar handling. Vehicles transported through Freight My Car arrive pre-cleared for road use, allowing immediate mobility upon arrival.

Vehicle air freight is preferred among clients seeking reduced handling times and more control over arrival schedules compared to maritime alternatives. Air transport minimizes exposure to environmental elements and allows vehicles to reach destination airports in a matter of days, rather than weeks. This model is particularly useful for travelers attending seasonal events, relocating temporarily, or planning multi-country road journeys.

Freight My Car has reported that clients increasingly request enclosed ground delivery in Europe to protect vehicle condition during final-mile handling. These specialized services are available through pre-booked carriers aligned with the company’s European logistics network.

To manage increased demand, Freight My Car has scaled operational capacity during peak summer months and is working with airline partners to secure additional flight slots for vehicle cargo. The company is also exploring options for additional European destination hubs, including Italy and Morocco, to meet anticipated client interest in new travel corridors.

A notable trend observed in recent months includes returning customers scheduling multiple shipments annually—sending their vehicles to Europe in summer and back to the UAE in autumn. This indicates a pattern of seasonal mobility becoming a recurring routine among a segment of the UAE’s high-net-worth population.

The service is also seeing uptake from business travelers who maintain residences across both regions. Shipping a personal vehicle allows continuity in daily routines, particularly for clients with specific driving preferences, custom vehicle modifications, or high-dependency travel habits.

Freight My Car’s procedures are structured to ensure that each vehicle shipment is traceable, secure, and in compliance with regulatory standards. The company adheres to UAE export laws and destination country import rules, including emission compliance, roadworthiness, and registration protocols where applicable.

The company continues to focus on strict logistics compliance and high-security handling of all vehicle shipments.

Media Contact
Company Name: Freight My Car
Contact Person: Rinkle Vaz – Public Relations Manager
Email: Send Email
Phone: +971-56-2444231
Address:Latifa Tower, Trade Center Area
City: Dubai
Country: United Arab Emirates
Website: https://www.freightmycar.com

Potomac Truck Center Tidewater DBa TMI Truck & Equipment Unveils Expanded Services in Chesapeake

Potomac Truck Center Tidewater DBa TMI Truck & Equipment is a trusted provider of commercial trucks, semi-trucks, and equipment in Chesapeake. Known for quality inventory and expert service, the company supports a wide range of industries with reliable solutions tailored to meet demanding operational and transportation needs across the region.

July 5, 2025 – Chesapeake, VA – They proudly announced the expansion of their service offerings in Chesapeake. This initiative aims to cater comprehensively to the diverse needs of commercial truck and equipment enthusiasts in the region.

Enhanced Equipment Solutions

The company’s commitment to providing top-tier Equipment Chesapeake remains steadfast. With a robust inventory and a reputation for reliability, TMI Truck & Equipment ensures that businesses and individuals find the right tools to enhance their operations seamlessly.

Wide Range of Commercial Trucks

As leaders in Commercial Trucks Chesapeake, TMI Truck & Equipment introduces a wider selection of vehicles designed to meet various commercial needs. From heavy-duty to specialized trucks, customers can expect unparalleled quality and service excellence.

Premium Semi-Trucks Collection

In response to growing demand, TMI Truck & Equipment expands its lineup of Semi Trucks in Chesapeake. These vehicles are meticulously selected to offer optimal performance, reliability, and efficiency, supporting businesses in achieving their transportation goals effectively.

Seamless Online Experience

For more information about TMI Truck & Equipment’s expanded services and product offerings, visit their official website. Discover how their commitment to excellence in equipment, commercial trucks, and semi-trucks can elevate your business operations in Chesapeake.

About Potomac Truck Center Tidewater DBa TMI Truck & Equipment

Potomac Truck Center Tidewater DBa TMI Truck & Equipment is a leading provider of commercial trucks, equipment, and semi-trucks in Chesapeake, dedicated to delivering quality solutions and outstanding customer service. With a focus on meeting diverse industry needs, TMI Truck & Equipment continues to expand its footprint, ensuring accessibility and reliability for all clients.

Media Contact
Company Name: Potomac Truck Center Tidewater DBa TMI Truck & Equipment
Contact Person: Tracee Ransom
Email: Send Email
Phone: (757) 547-7151
Address:301 Bulldog Dr
City: Chesapeake
State: VA
Country: United States
Website: https://tmitruck.com/

Wonderwall Window Cleaning and Pressure Washing Announces Service Upgrades in Irving

Wonderwall Window Cleaning and Pressure Washing has introduced a series of service enhancements to address evolving property maintenance needs across the Irving area. By refining its techniques, updating its equipment, and expanding crew training, the company aims to deliver reliable results and a smoother experience for both residential and commercial clients.

Elevated Pressure Cleaning Services

The newly optimized pressure washing Irving division employs high-efficiency nozzles and biodegradable detergents to remove stubborn grime, oil stains, and mildew from driveways, patios, and siding. Technicians perform thorough pre-treatment assessments, adjusting water pressure to match surface conditions and prevent damage. Detailed post-wash inspections ensure every square foot meets exacting cleanliness standards and protects surrounding landscaping.

Advanced Surface Renewal with Power Washing

Building on core cleaning protocols, the expanded power washing Irving program now incorporates heated-water units for enhanced grease and gum removal in high-traffic areas. Equipment upgrades include adjustable wand angles for precise control around trim and fixtures, streamlining the restoration of decks, fences, and commercial façades. Service teams follow a consistent workflow—surface testing, targeted wash cycles, and final walkthrough—to uphold both efficiency and quality.

Comprehensive Window Care Offerings

Responding to homeowner feedback, the company has expanded its window cleaning services near me to include water-fed pole systems and streak-free squeegee techniques. Whether handling ground-level casements or multi-story storefronts, technicians adapt their methods to suit each glass type, frame material, and architectural feature. Safe-access equipment and fall-protection measures guarantee thorough interior and exterior cleanings without compromising safety or view clarity.

Community Engagement and Professional Standards

Active involvement in local business associations and neighborhood improvement projects underscores a commitment to Irving’s community wellbeing. Regular safety drills, equipment audits, and continuing-education courses reinforce a culture of responsibility on every job site. Clear communication channels—ranging from digital progress photos to concise service summaries—help property managers and homeowners stay informed throughout each project phase.

About Wonderwall Window Cleaning and Pressure Washing

Wonderwall Window Cleaning and Pressure Washing specializes in exterior cleaning solutions for residential, commercial, and industrial properties in North Texas. Offering a full suite of services—including soft-wash roof treatments, gutter cleaning, and specialty surface restoration—the company is fully licensed and insured. Through ongoing investment in technology, team development, and community partnerships, Wonderwall continues to elevate local property maintenance standards and support a cleaner, more vibrant Irving.

Media Contact
Company Name: Wonderwall Window Cleaning and Pressure Washing
Contact Person: Luis Rodriguez
Email: Send Email
Phone: (469) 202-9145
Address:800 Lake Carolyn Pkwy #248
City: Irving
State: TX
Country: United States
Website: https://dallasbestpressurewash.com/

Pichai Applauds Record-Breaking Success of THAIFEX – ANUGA ASIA 2025 Over 142,000 Visitors and Trade Value Surpassing 135 Billion Baht

BANGKOK, THAILAND – July 4th, 2025 – The Ministry of Commerce has officially announced the tremendous success of THAIFEX – ANUGA ASIA 2025, Asia’s leading food and beverage trade show held at IMPACT Muang Thong Thani. The event drew an overwhelming response from international buyers and industry professionals, reaffirming Thailand’s role as a regional food trade hub and a vital contributor to global food security. It also served as a key platform for advancing the “Thai Kitchen to the World” policy and further enhancing Thailand’s trade competitiveness on the global stage.

Mr. Pichai Naripthaphan, Minister of Commerce, stated that the success of THAIFEX – ANUGA ASIA 2025 not only reaffirmed the capabilities of Thai entrepreneurs, but also clearly demonstrated the growing international interest in Thailand’s food industry. This momentum aligns with the Soft Power strategy of Prime Minister Paetongtarn Shinawatra’s administration, which aims to elevate Thai cuisine as a global cultural and economic strength.

“The event received strong interest from international business communities, creating tangible trade opportunities for Thai entrepreneurs — particularly SMEs and startups,” said Mr. Phichai. “It also delivered a positive impact on the grassroots economy by generating income and employment across various regions nationwide.”

The event attracted strong interest from international trade visitors, generating tangible business opportunities for Thai entrepreneurs. In particular, SMEs and startups gained increased visibility and valuable business connections. The event also contributed to Thailand’s grassroots economy by driving income generation and job creation across local communities nationwide.

THAIFEX – ANUGA ASIA 2025 marked another milestone in its global presence and industry influence. This year’s edition featured 3,231 exhibitors across 6,208 booths, representing 57 countries — including 1,184 Thai exhibitors and 2,047 international exhibitors. The event welcomed a total of 142,370 visitors, comprising 88,349 trade visitors (20,566 international and 67,783 domestic), along with over 54,021 public visitors on the final day.

In terms of economic value, THAIFEX – ANUGA ASIA 2025 generated a total trade value of 135.68 billion baht. This comprised 135.45 billion baht during the trade days — including 271.81 million baht in immediate orders and an estimated 135.18 billion baht in projected orders within one year. Additionally, retail sales on the public day accounted for 227.82 million baht. Notably, trade generated by Thai exhibitors alone totaled 99.10 billion baht.

The event is jointly organised by three key partners — the Department of International Trade Promotion (DITP), Ministry of Commerce; the Thai Chamber of Commerce; and Koelnmesse — who are now gearing up for an even larger and more impactful edition in 2026. THAIFEX – ANUGA ASIA 2026 is set to further elevate the show to the international stage, featuring global food trends and cutting-edge innovations. The event will take place from 26–30 May 2026 at IMPACT Muang Thong Thani.

For more information, please visit www.thaifex-anuga.com or follow us on Facebook: THAIFEX – Anuga Asia.

Media Contact
Company Name: Integrated Communication Co., Ltd.
Contact Person: Usanee Thavornkarn
Email: Send Email
Phone: 081 984 5500
City: Bangkok
Country: Thailand
Website: www.incom.co.th

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pichai Applauds Record-Breaking Success of THAIFEX – ANUGA ASIA 2025 Over 142,000 Visitors and Trade Value Surpassing 135 Billion Baht

Dee Agarwal on Recognizing Industries That Are Ripe for Disruption

Dee Agarwal explores how to spot industries ripe for disruption by identifying inefficiencies, outdated assumptions, and cultural lag, urging innovators to look beyond technology and listen closely to what consumers and systems quietly reveal.

ATLANTA, GA – July 4th, 2025 – In the dynamic landscape of modern commerce, innovation is not a mere advantage; it is an existential necessity. Yet while some sectors evolve continuously, others linger in outdated paradigms, creating fertile ground for those with the vision to disrupt. According to Deepak (Dee) Agarwal, an innovative founder with experience in multiple industries, recognizing the conditions that precede transformation is as much a matter of pattern recognition as it is strategic foresight.

“Industries rarely shout that they’re ready for disruption,” says Dee Agarwal. “But they whisper. The key is listening closely to inefficiencies that have been normalized.”

At its core, disruption does not simply involve digitizing analog processes or streamlining supply chains. Rather, Dee Agarwal argues, true disruption stems from challenging a system’s foundational assumptions, often those left unquestioned for decades.

“If an industry still operates as though recent advancements haven’t fundamentally changed consumer expectations, that’s your first signal,” Indicators of Latent Vulnerability

Dee Agarwal identifies several recurring characteristics that suggest an industry is ripe for reinvention. Chief among them is opacity, especially in pricing or service standards. Sectors where customers feel they are navigating a black box tend to be prime targets.

“When consumers can’t easily compare costs, timelines, or outcomes, incumbents are often relying on that confusion to maintain margins. That’s not sustainable,” says Dee Agarwal. “Disruptors thrive in sunlight.”

Another telltale sign is industries where technological inertia is disguised as regulation. While compliance and governance frameworks are necessary, Dee Agarwal cautions against conflating them with immutability.

“Highly regulated sectors like healthcare and finance are often assumed to be off-limits, but regulation isn’t the enemy of innovation,” Dee Agarwal says. “In many cases, it’s simply a design constraint, and ironically, the limits we’re given often unlock our most original ideas.”

Pain Points as Entry Points

Rather than focusing on industry size or market capitalization as indicators of opportunity, Dee Agarwal encourages founders and investors alike to concentrate on friction, especially the kind experienced by end-users.

“Disruption doesn’t begin with the product. It begins with a deep discomfort,” Dee Agarwal explains. “When users feel trapped in complexity, slow timelines, or bureaucratic systems, they’re not just open to change, they’re starving for it. When people only interact with an industry out of necessity—and dread the experience each time—that’s not just inertia. That’s a clear sign that the incumbents have deprioritized the customer. It’s an open invitation for change.”

The Myth of Market Saturation

One of the more persistent fallacies in business is the idea that some industries are simply “done,” that all major problems have been solved, or that margins are too thin for worthwhile entry. Dee Agarwal is quick to reject this thinking.

“Mature markets don’t mean dead markets,” he says. “It means there’s an orthodoxy entrenched, and orthodoxy is exactly what disruption targets.”

In fact, some of the most heavily penetrated sectors, like consumer packaged goods or transportation, continue to see waves of new entrants not because they are easy to navigate, but because consumer expectations continue to evolve faster than incumbent innovation.

“While legacy players often design for yesterday’s customer, the disruptor designs for tomorrow’s,” Dee Agarwal adds. “That delta is the opportunity.”

The Role of Cultural Lag

Beyond technology and regulation, Dee Agarwal highlights what he calls “cultural lag,” a condition in which institutional behavior fails to keep pace with social or generational shifts. Industries that ignore generational expectations around speed, sustainability, transparency, or equity, he argues, are living on borrowed time.

“You don’t need to be radical to be a disruptor,” Dee Agarwal notes. “You just need to be aligned with reality faster than everyone else.”

He points to shifting attitudes around mental health, privacy, and remote work as cultural indicators of change that are often more predictive than quarterly earnings or analyst projections.

“Disruptors aren’t just technologists or marketers. They’re sociologists in disguise,” Dee Agarwal says.

Looking Ahead

For executives, investors, and founders seeking their next frontier, the path forward doesn’t require clairvoyance. It demands attentiveness. In a world defined by the compression of time, patience, and resources, sectors slow to adapt are the ones most likely to be overtaken.

“The question isn’t whether an industry can be disrupted,” says Dee Agarwal. “It’s whether someone’s willing to see what others are too comfortable to question.”

In an era where disruption has become a buzzword, Dee Agarwal’s insights offer a return to first principles: that the most profound innovation often arises not from invention, but from interrogation.

Media Contact
Company Name: Cambridge Global
Contact Person: Andrew Mitchell
Email: Send Email
Phone: 404-955-7133
Country: United States
Website: https://deeagarwal.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dee Agarwal on Recognizing Industries That Are Ripe for Disruption

Hawaii Insurance Agency Releases Guide on Building a Business Disaster Recovery Plan

Atlas Insurance Agency, a Hawaii-based business insurance advisory firm, has published a guide to help Hawaii businesses create effective disaster recovery plans that strengthen post-disruption resilience.

Honolulu, Hawaii – July 4, 2025 – Atlas Insurance Agency, a Hawaii business insurance consulting firm , has released a new blog post to assist Hawaii-based businesses in building robust disaster recovery plans to support prompt recovery after disruptive events. The article, titled “How to Build an Effective Disaster Recovery Plan,” outlines key steps businesses should take to minimize downtime, restore critical operations, and coordinate recovery efforts in the wake of weather events, cyberattacks, equipment failure, or other unexpected disasters.

The blog explains the purpose of a disaster recovery plan (DRP), how it differs from a business continuity plan, and lays out a seven-step approach for constructing one. These steps include conducting a risk and impact assessment, identifying business-critical systems, defining recovery time and point objectives, assigning roles and responsibilities, developing backup procedures, testing plans through drills, and implementing structured communication strategies.

Hawaii businesses are uniquely exposed to hazards such as hurricanes, flooding, and unpredictable surges in visitor activity, which can cause significant disruption. The blog encourages organizations to coordinate with risk and insurance consultants to close potential coverage gaps and develop response procedures aligned with their industry-specific risks.

In addition to general best practices, the article introduces critical planning concepts, including the 3-2-1 rule for data redundancy and the “4 C’s” of disaster recovery—communication, coordination, continuity, and collaboration. These principles are presented as frameworks to help businesses respond more effectively during recovery phases.

The new blog post reflects Atlas Insurance’s ongoing commitment to helping clients build risk-informed operational strategies in an evolving threat environment. By supporting thorough recovery planning, Atlas Insurance enables Hawaii businesses to resume activity more quickly and limit long-term loss following unplanned disruptions.

To learn more about disaster recovery planning or to speak with an advisor, contact Atlas Insurance Agency at (808) 400-6680 or visit their website at https://www.atlasinsurance.com/. Atlas Insurance is headquartered at 201 Merchant Street, Suite 1100, Honolulu, HI 96813.

Media Contact
Company Name: Atlas Insurance Agency
Contact Person: Chason Ishii
Email: Send Email
Phone: (808) 400-6680
Address:201 Merchant Street, Suite 1100
City: Honolulu
State: Hawaii
Country: United States
Website: https://www.atlasinsurance.com/

MADMIA and Peppa Pig Introduces New Sock for Kids and Adults

MADMIA teams up with a beloved children’s brand to launch a playful new design that brings imagination, color, and character to every step this season.

USA – July 4, 2025 – MADMIA has released a joyful new design that brings a beloved children’s character into the world of bold fashion, the Peppa Pig George Socks. Created in collaboration with the global Peppa Pig brand, this vibrant new pair of funny socks for boys and girls features George Pig and his favorite dinosaur, making it a standout addition for kids, parents, and fans of playful style.

funny-socks-for-boys

These funny socks for adults arrive in MADMIA’s most popular size, made to fit ages 6 to 99, while also suiting children aged 3 to 5 comfortably. The Peppa Pig George Socks is priced at $19.93 AUD and they make a perfect gift or wardrobe update for fans who want to stand out.

“This collaboration gave us the chance to bring more than a character to life. It gave us the chance to connect with imagination. George Pig represents curiosity and fun. With this design, we translated those qualities into a wearable experience that speaks to kids and adults alike,” a spokesperson said.

Orders ship the same day within Australia and the next business day in the US. MADMIA provides free shipping on all orders over $75.00 AUD within Australia and the United States. For orders of funny socks for girls below that, shipping costs are $9.90 AUD for Australia and $11.90 AUD for the US. European customers receive flat-rate shipping at $14.90 AUD for orders under $155.00 AUD.

MADMIA also offers a return policy on their funny socks for women and men. Items must be returned within 30 days of purchase, must be unworn with original tags, and must be kept in original packaging to receive a refund.

“We’ve always believed socks can do more than keep your feet warm, and they can spark joy. With George Pig on board, we’ve created a design that delivers happiness with every step. It’s more than fashion, it’s a bit of childhood nostalgia that walks with you,” the spokesperson said.

The Peppa Pig George Socks join MADMIA’s wider collection of funny socks for kids. The full lineup blends bold design with fun-loving spirit, offering something unique for every personality.

For those searching “funny socks near me“, The Peppa Pig George Socks are available for purchase on MADMIA’s website.

About Company:

MADMIA is an Australian-based brand dedicated to creating crazy socks that are bold, unique, and full of personality. With designs that inspire happiness and self-expression, MADMIA is redefining the way people wear socks. Visit https://www.madmia.com/

Media Contact
Company Name: MADMIA
Contact Person: Tanja Filipovska
Email: Send Email
Phone: 0449872883
Country: United States
Website: https://www.madmia.com/

Chronic Urticaria Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Chronic Urticaria Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Chronic Urticaria pipeline landscape. It covers the Chronic Urticaria pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Urticaria pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Chronic Urticaria Pipeline. Dive into DelveInsight’s comprehensive report today! @ Chronic Urticaria Pipeline Outlook

Key Takeaways from the Chronic Urticaria Pipeline Report

In July 2025, Novartis Pharmaceuticals announced a study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participants with Chronic Spontaneous Urticaria (CSU) who previously completed the treatment phase of remibrutinib preceding Phase 3 core studies. This study will also fulfill the Novartis commitment to provide post-trial access to participants who have completed the preceding Phase 3 studies, where applicable.
DelveInsight’s Chronic Urticaria Pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Chronic Urticaria treatment.
The leading Chronic Urticaria Companies such as Synermore Biologics, Incyte Corporation, Jasper Therapeutics, Novartis, Regeneron/Sanofi, Principia Biopharma, Enanta Pharmaceuticals, Granular Therapeutics, Blueprint Medicines, Newave Pharmaceutical, and others.
Promising Chronic Urticaria Pipeline Therapies such as Omalizumab (Xolair), BLU-808, AK002, Levocetirizine, Loratadine, Desloratadine, Povorcitinib, Bilastine, and others.

Stay ahead with the most recent pipeline outlook for Chronic Urticaria. Get insights into clinical trials, emerging therapies, and leading companies with Chronic Urticaria @ Chronic Urticaria Treatment Drugs

Chronic Urticaria Emerging Drugs Profile

CMAB007: Taizhou Mabtech Pharmaceutical Co.,Ltd

CMAB007 is a recombinant humanized anti-IgE monoclonal antibody developed by Taizhou Mabtech Pharmaceutical Co., Ltd., a subsidiary of Mabpharm Limited. Approved in China in May 2023, it is the first domestically produced therapeutic antibody for allergic asthma. CMAB007 is also undergoing Phase III clinical trials for chronic spontaneous urticaria in patients unresponsive to H1 antihistamines. As an omalizumab biosimilar, it targets IgE-mediated allergic diseases and has been included in China’s national health insurance catalogue, facilitating widespread adoption across healthcare institutions. Currently, the drug is in Phase III stage of its development for the treatment of Chronic Urticaria.

Povorcitinib – Incyte Corporation

Povorcitinib (INCB54707) is an oral small-molecule JAK1 inhibitor currently in Phase 3 clinical trials for hidradenitis suppurativa (HS) and vitiligo. A Phase 3 trial is being planned for prurigo nodularis (PN). Phase II studies of povorcitinib in PN, asthma and chronic spontaneous urticaria are also ongoing. Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with compound and use patents in certain countries/regions in the Territory. Currently, povorcitinib is in Phase III clinical trials for non-segmental vitiligo and HS in multiple countries outside of China. Currently, the drug is in Phase II stage of its development for the treatment of Chronic Urticaria.

Briquilimab: Jasper Therapeutics

Briquilimab (JSP191) is an unconjugated, aglycosylated, anti-c-Kit antibody that functionally blocks the interaction of the c-Kit receptor from its ligand, stem cell factor (SCF). The interaction of SCF and c-Kit is required for mast cells to survive. By blocking SCF from binding to c-Kit and disrupting the critical survival signal, briquilimab causes mast cells to undergo orderly cell death. For mast cell-driven diseases such as chronic urticaria, this removes the underlying source of the inflammatory response. In low-to-intermediate risk MDS, briquilimab blocks critical cell survival signals, depleting Kit-expressing MDS cells. For stem cell transplant, briquilimab blocks the ability of stem cells to recover from low intensity radiation, thereby opening the specific niches in the bone marrow for donor or gene-corrected hematopoietic stem cells to engraft. Currently, the drug is in Phase II stage of its development for the treatment of Chronic Urticaria.

The Chronic Urticaria Pipeline Report Provides Insights into-

The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Urticaria with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Urticaria Treatment.
Chronic Urticaria Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Chronic Urticaria Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Urticaria market

Explore groundbreaking therapies and clinical trials in the Chronic Urticaria Pipeline. Access DelveInsight’s detailed report now! @ New Chronic Urticaria Drugs

Chronic Urticaria Companies

Synermore Biologics, Incyte Corporation, Jasper Therapeutics, Novartis, Regeneron/Sanofi, Principia Biopharma, Enanta Pharmaceuticals, Granular Therapeutics, Blueprint Medicines, Newave Pharmaceutical, and others.

Chronic Urticaria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Chronic Urticaria Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Unveil the future of Chronic Urticaria Treatment. Learn about new drugs, Chronic Urticaria Pipeline developments, and key companies with DelveInsight’s expert analysis @ Chronic Urticaria Market Drivers and Barriers

Scope of the Chronic Urticaria Pipeline Report

Coverage- Global
Chronic Urticaria Companies- Synermore Biologics, Incyte Corporation, Jasper Therapeutics, Novartis, Regeneron/Sanofi, Principia Biopharma, Enanta Pharmaceuticals, Granular Therapeutics, Blueprint Medicines, Newave Pharmaceutical, and others.
Chronic Urticaria Pipeline Therapies- Omalizumab (Xolair), BLU-808, AK002, Levocetirizine, Loratadine, Desloratadine, Povorcitinib, Bilastine, and others.
Chronic Urticaria Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Chronic Urticaria Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Chronic Urticaria Pipeline Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Chronic Urticaria Companies, Key Products and Unmet Needs

Table of Contents

Introduction
Executive Summary
Chronic Urticaria: Overview
Pipeline Therapeutics
Therapeutic Assessment
Chronic Urticaria – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
CMAB007: Taizhou Mabtech Pharmaceutical Co.,Ltd
Mid Stage Products (Phase II)
Povorcitinib – Incyte Corporation
Early Stage Products (Phase I)
Briquilimab: Jasper Therapeutics
Preclinical and Discovery Stage Products
Drug Name: Company Name
Inactive Products
Chronic Urticaria Key Companies
Chronic Urticaria Key Products
Chronic Urticaria – Unmet Needs
Chronic Urticaria – Market Drivers and Barriers
Chronic Urticaria – Future Perspectives and Conclusion
Chronic Urticaria Analyst Views
Chronic Urticaria Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/chronic-urticaria-or-hives-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Urticaria Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Rheumatoid Arthritis Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Rheumatoid Arthritis Pipeline Insight, 2025” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Rheumatoid Arthritis (RA) pipeline landscape. It covers the Rheumatoid Arthritis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Rheumatoid Arthritis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Rheumatoid Arthritis Pipeline. Dive into DelveInsight’s comprehensive report today! @ Rheumatoid Arthritis Pipeline Outlook

Key Takeaways from the Rheumatoid Arthritis Pipeline Report

In July 2025, AbbVie conducted a study currently includes 3 substudies evaluating different treatments in participants with RA. Substudy 1 will evaluate lutikizumab monotherapy (treatment given alone) compared to placebo (looks like the study treatment but contains no medicine). Substudy 2 will evaluate ravagalimab monotherapy compared to placebo and Substudy 3 will evaluate lutikizumab and ravagalimab combination therapy (treatments given together) compared to placebo. Approximately 180 participants who have failed 1 or 2 biologic/targeted synthetic disease-modifying antirheumatic drug (tsDMARD) therapies will be enrolled in the study at approximately 65 sites worldwide.
DelveInsight’s Rheumatoid Arthritis Pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Rheumatoid Arthritis treatment.
The leading Rheumatoid Arthritis Companies such as Gedeon Richter, mAbxience Research S.L., AnaptysBio, Inc, Istesso, Synact Pharma, Sanofi, AstraZeneca, Cullinan Therapeutics, Sonoma Biotherapeutics, Immunovant, Inc, Janssen Research & Development, LLC, Ernexa Therapeutics Inc., Kymera Therapeutics, Inc., Eli Lilly and Company, Rise Therapeutics LLC, Artiva Biotherapeutics, Inc., SinoMab BioScience Limited, ECM Therapeutics, Hangzhou Highlightll Pharmaceutical Co., Ltd, Beijing VDJBio Co., LTD., AbbVie, ILAb Co., Ltd., Sonoma Biotherapeutics, Inc., Gilead Sciences, Zenas BioPharma (USA), LLC, Flerie AB, Spyre Therapeutics, Inc, Candid Therapeutics, Inc., LAPIX Therapeutics and others.
Promising Rheumatoid Arthritis Pipeline Therapies such as BMS-582949, Etanercept, Lutikizumab, Ravagalimab, Filgotinib Maleate, IMVT-1402, TLL-018, CPL409116, LY3541860 and others.

Stay ahead with the most recent pipeline outlook for Rheumatoid Arthritis. Get insights into clinical trials, emerging therapies, and leading companies with Rheumatoid Arthritis @ Rheumatoid Arthritis Treatment Drugs

Rheumatoid Arthritis Emerging Drugs Profile

RGB-19: Gedeon Richter

RGB-19, developed by Gedeon Richter in collaboration with Mochida Pharmaceutical, is a biosimilar version of tocilizumab, a monoclonal antibody that inhibits interleukin-6 (IL-6) signaling, which plays a central role in the inflammation associated with rheumatoid arthritis. By targeting IL-6, RGB-19 aims to reduce inflammation and alleviate symptoms in patients with rheumatoid arthritis and other immune-mediated conditions. As a biosimilar to the reference product RoActemra®, RGB-19 is designed to offer comparable efficacy and safety, while providing a more affordable therapeutic option to patients worldwide, thereby expanding access to this important biological treatmentCurrently, the drug is registered for the treatment of Rheumatoid Arthritis (RA).

MB04: mAbxience Research S.L.

MB04, developed by mAbxience Research S.L., is a biosimilar to etanercept designed for the treatment of rheumatoid arthritis and other autoimmune diseases. It is an Fc fusion protein that targets and inhibits both tumor necrosis factor alpha (TNF-α) and lymphotoxin alpha (LTα, also known as TNF-β), key cytokines involved in the inflammatory processes underlying rheumatoid arthritis. By blocking these cytokines, MB04 aims to reduce inflammation and alleviate symptoms associated with immune-mediated joint damage. As a biosimilar, MB04 is intended to offer comparable efficacy and safety to the reference biologic (Enbrel®), while potentially improving access and affordability for patients requiring long-term management of rheumatoid arthritis. Currently, the drug is in Phase III stage of its development for the treatment of Rheumatoid Arthritis (RA).

Rosnilimab: AnaptysBio, Inc

Rosnilimab is a novel therapeutic antibody that directly targets PD-1, a co-inhibitory receptor preferentially expressed on the surface of activated T cells, which broadly impacts the pathogenic drivers of inflammatory diseases such as RA and UC. Rosnilimab is a targeted therapy designed to deplete PD-1high T cells and agonize the remaining PD-1+ T cells to restore the immune system back to a state of homeostasis. This is anticipated to result in specific immunological outcomes in both inflamed tissue and the periphery, such as reduction in T cell proliferation, migration and cytokine secretion, and reduction of plasma cell generation and autoantibody levels. Currently, the drug is in Phase II stage of its development for the treatment of Rheumatoid Arthritis (RA).

Leramistat: Istesso

Leramistat is an oral treatment that selectively modulates inflammation at the level of tissue damage, adapting to stimulus strength. By avoiding outright inhibition of inflammatory cytokine cascades and promoting a pro-repair environment, leramistat fine-tunes control of subclinical inflammation and restores normal bone dynamics to resolve rheumatoid pathology at its source. With its unique “pro-repair” mechanism, leramistat offers a new foundational option for combination therapy, enabling other disease-modifying treatments to work better for longer and elevating the definition of remission. Currently, the drug is in Phase II stage of its development for the treatment of Rheumatoid Arthritis (RA).

AP1189: Synact Pharma

SynAct Pharma’s drug candidate, resomelagon (AP1189), is a once-daily oral biased melanocortin receptor type 1 and 3 (MC1r and MC3r) agonist. The pharmacological effects of the compound are mediated by its ability to balance ongoing inflammation and bringing the immune system in a given inflamed tissue, organ, or circulation to a new homeostatic state with less proinflammatory activity and activation of pro-resolving pathways. This effect is distinct from suppression of the immune system, which may cause unwanted side effects, such as increased risk of infections and other side effects. The mode of action is specifically interesting to apply in active inflammation, including early active states of chronic inflammatory/autoimmune diseases and in hyperinflammatory states of infectious diseases where the benefit of applying immunosuppressive drugs is outweighed by the risk of use. The selectivity of resomelagon (AP1189) to MC1r and MC3r means that MC2r mediated glucocorticoid release from the adrenal gland is avoided. Thus, the compound induces its pharmacological effects in a steroid-free manner without the significant safety, tolerability, and side effect issues associated with adrenocorticotropic hormone (ACTH) based therapies. Further to that, the compound stimulates the MC1r through biased agonism, activating an alternative pathway, so the compound can be given without the unwanted side effect of skin hyperpigmentation that classical MC1r agonists will induce though cAMP activation in melanocytes. Currently, the drug is in Phase II stage of its development for the treatment of Rheumatoid Arthritis (RA).

LPX-TI641: LAPIX Therapeutics

LPX-TI641 is an oral, small-molecule designed to bind the phosphatidylserine binding pocket on the T cell/transmembrane, immunoglobulin, and mucin (Tim) family of receptors. It is currently under clinical development for autoimmune indications such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and multiple sclerosis with plans to expand to other autoimmune indications where the underlying pathology involves immune imbalances and loss of self-tolerance. LPX-TI641’s primary pharmacology works to restore the adaptive immune system’s self-tolerance rather than suppressing immunity, enabling patients to more effectively and gently combat autoimmune disease. Toxicological studies and emerging clinical data show that LPX-TI641 does not induce neutropenia or lymphocytopenia, suggesting a potentially improved safety profile compared to current therapies. Currently, the drug is in Phase I stage of its development for the treatment of Rheumatoid Arthritis (RA).

The Rheumatoid Arthritis Pipeline Report Provides Insights into-

The report provides detailed insights about companies that are developing therapies for the treatment of Rheumatoid Arthritis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Rheumatoid Arthritis Treatment.
Rheumatoid Arthritis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Rheumatoid Arthritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Rheumatoid Arthritis market

Explore groundbreaking therapies and clinical trials in the Rheumatoid Arthritis Pipeline. Access DelveInsight’s detailed report now! @ New Rheumatoid Arthritis Drugs

Rheumatoid Arthritis Companies

Gedeon Richter, mAbxience Research S.L., AnaptysBio, Inc, Istesso, Synact Pharma, Sanofi, AstraZeneca, Cullinan Therapeutics, Sonoma Biotherapeutics, Immunovant, Inc, Janssen Research & Development, LLC, Ernexa Therapeutics Inc., Kymera Therapeutics, Inc., Eli Lilly and Company, Rise Therapeutics LLC, Artiva Biotherapeutics, Inc., SinoMab BioScience Limited, ECM Therapeutics, Hangzhou Highlightll Pharmaceutical Co., Ltd, Beijing VDJBio Co., LTD., AbbVie, ILAb Co., Ltd., Sonoma Biotherapeutics, Inc., Gilead Sciences, Zenas BioPharma (USA), LLC, Flerie AB, Spyre Therapeutics, Inc, Candid Therapeutics, Inc., LAPIX Therapeutics and others.

Rheumatoid Arthritis (RA) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Rheumatoid Arthritis Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Unveil the future of Rheumatoid Arthritis Treatment. Learn about new drugs, Rheumatoid Arthritis Pipeline developments, and key companies with DelveInsight’s expert analysis @ Rheumatoid Arthritis Market Drivers and Barriers

Scope of the Rheumatoid Arthritis Pipeline Report

Coverage- Global
Rheumatoid Arthritis Companies- Gedeon Richter, mAbxience Research S.L., AnaptysBio, Inc, Istesso, Synact Pharma, Sanofi, AstraZeneca, Cullinan Therapeutics, Sonoma Biotherapeutics, Immunovant, Inc, Janssen Research & Development, LLC, Ernexa Therapeutics Inc., Kymera Therapeutics, Inc., Eli Lilly and Company, Rise Therapeutics LLC, Artiva Biotherapeutics, Inc., SinoMab BioScience Limited, ECM Therapeutics, Hangzhou Highlightll Pharmaceutical Co., Ltd, Beijing VDJBio Co., LTD., AbbVie, ILAb Co., Ltd., Sonoma Biotherapeutics, Inc., Gilead Sciences, Zenas BioPharma (USA), LLC, Flerie AB, Spyre Therapeutics, Inc, Candid Therapeutics, Inc., LAPIX Therapeutics and others.
Rheumatoid Arthritis Pipeline Therapies- BMS-582949, Etanercept, Lutikizumab, Ravagalimab, Filgotinib Maleate, IMVT-1402, TLL-018, CPL409116, LY3541860 and others.
Rheumatoid Arthritis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Rheumatoid Arthritis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Rheumatoid Arthritis Pipeline Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Rheumatoid Arthritis Companies, Key Products and Unmet Needs

Table of Contents

Introduction
Executive Summary
Rheumatoid Arthritis (RA): Overview
Pipeline Therapeutics
Therapeutic Assessment
Rheumatoid Arthritis (RA)– DelveInsight’s Analytical Perspective
Late Stage Products (Registration)
RGB-19: Gedeon Richter
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
AP1189: Synact Pharma
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
LPX-TI641: LAPIX Therapeutics
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Rheumatoid Arthritis (RA) Key Companies
Rheumatoid Arthritis (RA) Key Products
Rheumatoid Arthritis (RA)- Unmet Needs
Rheumatoid Arthritis (RA)- Market Drivers and Barriers
Rheumatoid Arthritis (RA)- Future Perspectives and Conclusion
Rheumatoid Arthritis (RA) Analyst Views
Rheumatoid Arthritis (RA) Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Rheumatoid Arthritis Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight